4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

521.43p
   
  • Change Today:
    -8.57p
  • 52 Week High: 785.00
  • 52 Week Low: 440.83
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 0
  • Market Cap: £81.02m
  • Beta: 0.00

4basebio Overview

4basebio UK Societas ("4bb" or "the Company") is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing Good Manufacturing Practice ("GMP") grade DNA, suitable for use in gene therapies and DNA vaccines.

Key Personnel

CEO: Amy Walker
CFO: David John Roth
COO: Scott Lorimer
Executive Chairman: Manja Hermina Elisabeth Maria Boerman
Independent Non-Executive Director: Alan Malus
Non-Executive Dir: Heikki Lanckriet, Hansjörg Plaggemars, Michael Wasserman, Alexander Link, Cornel Chiriac

Contact Details

Address: 25 Norman Way, Over, Cambridge, United Kingdom, CB24 5QE
Phone: +44 (0)1223 967943
Website: http://www.4basebio.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BMCLYF79

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 521.43p
Change Today -8.57p
% Change -1.62 %
52 Week High 785.00
52 Week Low 440.83
Volume 0
Shares Issued 15.54m
Market Cap £81.02m
Beta 0.00

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.8% below the market average61.8% below the market average61.8% below the market average61.8% below the market average61.8% below the market average
26.83% below the sector average26.83% below the sector average26.83% below the sector average26.83% below the sector average26.83% below the sector average
Price Trend
85.17% below the market average85.17% below the market average85.17% below the market average85.17% below the market average85.17% below the market average
53.49% below the sector average53.49% below the sector average53.49% below the sector average53.49% below the sector average53.49% below the sector average
Income Not Available
Growth
62.26% above the market average62.26% above the market average62.26% above the market average62.26% above the market average62.26% above the market average
92.86% above the sector average92.86% above the sector average92.86% above the sector average92.86% above the sector average92.86% above the sector average

4basebio Dividends

No dividends found

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

4basebio Key Personnel

CFO David John Roth
CEO Amy Walker
COO Scott Lorimer

Top of Page